![](https://www.microbiometimes.com/wp-content/uploads/2024/07/shutterstock_2386290637-960x438.jpg)
Editor’s Choice
![](https://www.microbiometimes.com/wp-content/uploads/2024/07/Screenshot-2024-07-10-at-20.26.56-326x245.png)
Eligo Publishes a Landmark Study in Nature That Unlocks Genome Editing of Bacteria in the Gut
Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, publishes a landmark study in Nature that unlocks Genome Editing of Bacteria in the Gut. […]
![](https://www.microbiometimes.com/wp-content/uploads/2024/06/shutterstock_2221001821-326x245.jpg)
A New Path Toward Microbiome-Informed Precision Nutrition
ISB microbiome researchers have shown that microbial community-scale metabolic modeling can predict personalized short-chain-fatty-acid production profiles in the human gut. Their findings were published in the journal Nature Microbiology. Short-chain fatty acids (SCFAs) are beneficial […]
![](https://www.microbiometimes.com/wp-content/uploads/2024/06/Microbiome-Times-Lucien-326x245.png)
A Synbiotic Step Forward: Dr Lucien Harthoorn talks Synbiotic science, and Clasado’s collaboration with Probi
In what Clasado Biosciences described as “an exciting step forward” for the synbiotic supplement category, the prebiotic specialist recently published a new study in collaboration with probiotic manufacturer, Probi, which demonstrated a synergistic benefit of […]
In Case you Missed it:
![](https://www.microbiometimes.com/wp-content/uploads/2024/07/shutterstock_2036769314-326x245.jpg)
Mayo scientists developing at-home swab tests for endometrial, ovarian cancer
Early detection improves treatment outcomes for endometrial and ovarian cancers, yet far too often women are diagnosed in advanced stages of these diseases. Unlike many other cancers, there are no standard screenings for early detection […]
![](https://www.microbiometimes.com/wp-content/uploads/2024/07/shutterstock_1175298532-1-326x245.jpg)
SNIPR Biome receives funding for the development of CRISPR-medicines to improve EED in pregnant women
SNIPR BIOME receives funding from the Bill & Melinda Gates Foundation to accelerate the development of SNIPR Biome’s microbial gene therapy platform to improve Environmental Enteric Dysfunction (EED) in pregnant women from low- and middle-income […]
![](https://www.microbiometimes.com/wp-content/uploads/2024/06/shutterstock_2221001821-326x245.jpg)
A New Path Toward Microbiome-Informed Precision Nutrition
ISB microbiome researchers have shown that microbial community-scale metabolic modeling can predict personalized short-chain-fatty-acid production profiles in the human gut. Their findings were published in the journal Nature Microbiology. Short-chain fatty acids (SCFAs) are beneficial […]
![](https://www.microbiometimes.com/wp-content/uploads/2024/06/shutterstock_1684646683-326x245.jpg)
Resiliency shaped by activity in the gut microbiome and brain
A new UCLA Health study has found that resilient people exhibit neural activity in the brain regions associated with improved cognition and regulating of emotions, and were more mindful and better at describing their feelings. […]
![](https://www.microbiometimes.com/wp-content/uploads/2024/06/shutterstock_2356211335-326x245.jpg)
AxisBiotix Acne food supplement consumer study reports positive data
SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that AxisBiotix Limited (“AxisBiotix”), a wholly owned subsidiary of the Company, has finalised the analysis of the data from its AxisBiotix Acne […]
![](https://www.microbiometimes.com/wp-content/uploads/2024/06/Microbiome-Times-Lucien-326x245.png)
A Synbiotic Step Forward: Dr Lucien Harthoorn talks Synbiotic science, and Clasado’s collaboration with Probi
In what Clasado Biosciences described as “an exciting step forward” for the synbiotic supplement category, the prebiotic specialist recently published a new study in collaboration with probiotic manufacturer, Probi, which demonstrated a synergistic benefit of […]
![](https://www.microbiometimes.com/wp-content/uploads/2024/06/Screenshot-2024-06-06-at-15.18.42-326x245.png)
Seres Therapeutics Enters Into Memorandum Of Understanding For Vowst™ Asset Sale To Nestlé Health Science
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it has entered into a non-binding memorandum of understanding with Nestlé Health Science for the sale of Seres’ VOWST assets that will provide […]
![](https://www.microbiometimes.com/wp-content/uploads/2024/05/Screenshot-2024-05-29-at-17.49.26-326x245.png)
EUDRACAP® Select for oral targeting of sensitive microbiome: a case from development of functional coated capsule to clinical trial phase 1b
INTRODUCTION Formulating live biotherapeutics and accelerating drug development can be challenging. The following study focuses on the development of a customized functional coated capsule, EUDRACAP® Select, for the delivery of live biotherapeutics and demonstrates its […]